Clinical Trial: Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF?i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Anatomic Stage IV Breast Cancer AJCC v8
Study Type: INTERVENTIONAL
Official Title: Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF?i Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)
Brief Summary:
This phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal donor TGFBi NK cells with or without naxitamab work for the treatment of patients with GD2 expressing, HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic).Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells.TGFBi NK cells are manufactured cells that…
Read more